Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy

被引:16
|
作者
Nagalla, Srikanth [1 ]
Sarode, Ravi [1 ,2 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Div Hematol Oncol, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Div Transfus Med & Hemostasis, Dallas, TX 75390 USA
关键词
Antiplatelet therapy; Aspirin; P2Y12; inhibitors; Platelet transfusion; ACETYLSALICYLIC-ACID; ASPIRIN; CLOPIDOGREL; INHIBITION; PHARMACOLOGY; HEMORRHAGE; TICAGRELOR; REACTIVITY; SECONDARY; STROKE;
D O I
10.1016/j.tmrv.2019.01.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antiplatelet therapy is extensively used in the primary and secondary prophylaxis of arterial thrombotic disorders. Aspirin, the most commonly used antiplatelet agent, is a cyclooxygenase-1 inhibitor and considered a mild to moderate inhibitor of platelet function. Therefore, often a second antiplatelet agent is necessary in certain clinical conditions requiring greater inhibition of platelet function. An adenosine diphosphate (ADP) receptor, P2Y12, is an important target for this purpose; several agents inhibit this receptor providing potent antiplatelet effect. One of the side effects of these agents is bleeding, which in some patients may require reversal of antiplatelet effect. Similarly, patients undergoing emergent surgeries may benefit from reversal of antiplatelet effect to avoid excessive surgical bleeding. This article reviews current literature on this topic. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:92 / 97
页数:6
相关论文
共 50 条